Novartis's antimalarial Coartem gets US panel scrutiny
This article was originally published in Scrip
Novartis's NDA for the combination antimalarial, Coartem (artemether plus lumefantrine) will be reviewed by the US FDA's anti-infective drugs advisory panel on December 3rd. The proposed indication is treatment of acute, uncomplicated malaria infection caused by Plasmodium falciparum or mixed infections including P falciparum. The NDA is undergoing a priority review; it was submitted in June and a decision is expected by year-end. Coartem is approved in more than 80 countries and widely used in Africa, where Novartis said it has provided more than 195 million treatments without profit. If approved it would be the first artemisinin-based combination treatment licensed by the FDA. It also could become the first medicine approved under the new priority review voucher programme for tropical disease treatments that was established by the FDA Amendments Act.
You may also be interested in...
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
Agency is working with manufacturers, including Takeda and Emergent BioSolutions, to accelerate development of hyperimmune globulin products, with an eye toward starting clinical testing in several months; new FDA guidelines on convalescent plasma collection for single-patient emergency IND use are helpful in understanding agency expectations around source plasma collection for manufactured products as well, Emergent SVP Laura Saward says.